LumiThera's Valeda Light Delivery System Shows Extended Vision Benefits in Dry AMD Patients Over 4.5 Years
LumiThera's Valeda Light Delivery System, FDA-authorized in November 2024, demonstrated sustained vision improvement of over one line on the eye chart in more than 60% of dry AMD patients through 4.5 years of follow-up.
LumiThera's Valeda Light Delivery System Shows Sustained Vision Improvement in Dry AMD Patients
LumiThera's Valeda Light Delivery System, the first FDA-authorized non-invasive treatment for dry AMD, demonstrated sustained vision improvement of more than 5 letters on eye charts over 24 months in the LIGHTSITE IIIB extension study.
FDA Approves Light Therapy System for Dry Age-Related Macular Degeneration
The FDA has granted marketing authorization to LumiThera's Valeda Light Delivery System, a photobiomodulation (PBM) system, as the first treatment for dry age-related macular degeneration (AMD).
FDA Authorizes LumiThera's Valeda Light Delivery System for Dry AMD
The FDA has granted marketing authorization to LumiThera's Valeda Light Delivery System, marking the first authorized treatment for vision loss in dry age-related macular degeneration (AMD).
FDA Approves Valeda Light Delivery System for Dry Age-Related Macular Degeneration
The FDA has approved LumiThera's Valeda Light Delivery System, marking the first therapeutic option for adult patients with dry age-related macular degeneration (AMD).
FDA Approves LumiThera's Valeda Light Delivery System for Dry AMD
The FDA granted de novo authorization to LumiThera's Valeda Light Delivery System, marking the first approved treatment for vision loss related to dry age-related macular degeneration.
LumiThera's Valeda Light Delivery System Receives FDA Authorization for Dry AMD
LumiThera's Valeda Light Delivery System has been authorized by the FDA for treating vision loss in patients with dry age-related macular degeneration (AMD).